We are live on ! Find out more
LCM

Lynx1 Capital Management Portfolio holdings

AUM $633M
1-Year Est. Return 173.22%
This Fund
S&P 500
This Quarter Est. Return
+4.47%
1 Year Est. Return
+173.22%
3 Year Est. Return
+779.42%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$279M
AUM Growth
+$12.5M
Cap. Flow
+$53.7M
Cap. Flow %
19.23%
Top 10 Hldgs %
98.16%
Holding
20
New
2
Increased
5
Reduced
2
Closed
6

Top Buys

Rank Stock Value
1
PTGX icon
Protagonist Therapeutics
PTGX
+$30.7M
2
CGEM icon
Cullinan Oncology
CGEM
+$18.8M
3
GHRS icon
GH Research
GHRS
+$17.7M
4
STOK icon
Stoke Therapeutics
STOK
+$977K
5
CCCC icon
C4 Therapeutics
CCCC
+$732K

Top Sells

Rank Stock Value
1
KROS icon
Keros Therapeutics
KROS
+$8.61M
2
ALLK
Allakos
ALLK
+$4.39M
3
CRBU icon
Caribou Biosciences
CRBU
+$1.08M
4
VOR icon
Vor Biopharma
VOR
+$707K
5
MRUS
Merus
MRUS
+$523K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GHRS icon
1
GH Research
GHRS
$1.87B
$71.1M 25.45%
6,443,940
+1,584,946
+33% +$17.7M
MRUS
2
DELISTED
Merus
MRUS
$66M 23.65%
1,568,841
-12,000
-0.8% -$523K
PTGX icon
3
Protagonist Therapeutics
PTGX
$8.75B
$35.4M 12.69%
+733,014
New +$30.7M
STOK icon
4
Stoke Therapeutics
STOK
$1.82B
$35.2M 12.6%
5,291,929
+104,738
+2% +$977K
CGEM icon
5
Cullinan Oncology
CGEM
$1.05B
$24.3M 8.72%
3,215,722
+1,957,927
+156% +$18.8M
ALLO icon
6
Allogene Therapeutics
ALLO
$601M
$16.1M 5.78%
11,057,009
+182,286
+2% +$344K
CCCC icon
7
C4 Therapeutics
CCCC
$376M
$11.4M 4.07%
7,098,133
+245,389
+4% +$732K
TCRX icon
8
TScan Therapeutics
TCRX
$51.9M
$7.39M 2.65%
5,357,347
– –
DTIL icon
9
Precision BioSciences
DTIL
$188M
$3.65M 1.31%
766,051
– –
IBIO icon
10
iBio
IBIO
$71M
$3.47M 1.24%
862,279
– –
PASG icon
11
Passage Bio
PASG
$15.9M
$3.27M 1.17%
462,848
– –
UPB
12
Upstream Bio Inc
UPB
$349M
$1.34M 0.48%
219,247
-20,795
-9% -$199K
NEUP
13
Neuphoria Therapeutics
NEUP
$19.7M
$264K 0.09%
45,806
– –
DSGN icon
14
Design Therapeutics
DSGN
$736M
$255K 0.09%
+65,954
New +$315K
ALLK
15
DELISTED
Allakos
ALLK
– –
-3,628,144
Closed -$4.39M
CNTA
16
DELISTED
Centessa Pharmaceuticals
CNTA
– –
-17,400
Closed -$291K
CRBU icon
17
Caribou Biosciences
CRBU
$156M
– –
-680,189
Closed -$1.08M
KROS icon
18
Keros Therapeutics
KROS
$199M
– –
-544,001
Closed -$8.61M
RPTX
19
DELISTED
Repare Therapeutics
RPTX
– –
-79,176
Closed -$104K
VOR icon
20
Vor Biopharma
VOR
$1.04B
– –
-31,861
Closed -$707K

Similar funds

SWM
SilverOak Wealth Management Edina, Minnesota $632M AUM 18.6% 1-Year Est. Return
RFA
Rollins Financial Advisors New York City, New York $632M AUM 23.84% 1-Year Est. Return
WA
WFM Asia Road Town, Tortola, British Virgin Islands $632M AUM 14.51% 1-Year Est. Return
AMM
American Money Management Rancho Santa Fe, California $632M AUM 14.06% 1-Year Est. Return
EIM
Essex Investment Management Boston, Massachusetts $632M AUM 95.36% 1-Year Est. Return
SWP
Summit Wealth Partners Orlando, Florida $632M AUM 9.71% 1-Year Est. Return
ACM
Arini Captial Management London, United Kingdom $634M AUM
BI
BlueSpruce Investments Chicago, Illinois $631M AUM 11.83% 1-Year Est. Return

Lynx1 Capital Management's Q1 2025 Portfolio in Review

As of Q1 2025, Lynx1 Capital Management held 20 positions worth $279M, up 4.7% from $267M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Lynx1 Capital Management deployed $53.7M of net new capital in Q1 2025, opening 2 new positions and adding to 5 existing holdings. Its largest new stake was Protagonist Therapeutics: 733,014 shares worth $35.4M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

On the sell side, the largest reduction was Merus, an estimated $523K trimmed.

  • Lynx1 Capital Management's largest Q1 2025 buy was Protagonist Therapeutics: 733,014 shares worth $35.4M.
  • Lynx1 Capital Management added most to Cullinan Oncology in Q1 2025, an estimated $18.8M increase.
  • Lynx1 Capital Management's biggest Q1 2025 reduction was Merus, cutting an estimated $523K.
  • Lynx1 Capital Management fully exited Keros Therapeutics in Q1 2025, selling an estimated $8.61M.
  • Lynx1 Capital Management's ten largest holdings make up 98% of its $279M portfolio in Q1 2025.
  • Lynx1 Capital Management opened 2 new positions and closed 6 in Q1 2025.
  • Lynx1 Capital Management's portfolio value rose 4.7% quarter-over-quarter to $279M.

Based on Lynx1 Capital Management's 13F filing for Q1 2025, filed 15 May 2025.